Literature DB >> 21489742

Perioperative fast track program in intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery in advanced ovarian cancer.

P A Cascales Campos1, J Gil Martínez, P J Galindo Fernández, E Gil Gómez, I M Martínez Frutos, P Parrilla Paricio.   

Abstract

INTRODUCTION: Diffuse peritoneal dissemination in advanced ovarian cancer can be treated using optimal effort surgery involving peritonectomy procedures and the administration of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC).
OBJECTIVE: To report on our experience in the treatment of advanced ovarian cancer using peritonectomy procedures and HIPEC through the fast track program. PATIENTS AND
METHOD: From September 2008 until May 2010, forty-six patients with primary advanced (stage III-C) or recurrent ovarian cancer have been included in the fast track protocol if they had optimal cytoreduction CC-0 or CC-1 accompanied by HIPEC and there had no more than one digestive anastomosis.
RESULTS: The mean peritoneal cancer index (PCI) was 12.35 (3-21). The median operation time was 380 min (200-540). Optimal surgery CC-0 was achieved in 38 of the 46 patients and CC-1 in the remaining 8. Mean postoperative hospital stay was 6.94 ± 1.56 days (3-11). Major morbidity rates were 15.3%. Paralytic ileus was the most frequent of these. There was no mortality related to the procedure.
CONCLUSION: Surgery with peritonectomy procedures and HIPEC in advanced ovarian carcinoma is possible under fast track surgery programs in patients with low volume peritoneal carcinomatosis. Prospective and randomized studies are needed.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21489742     DOI: 10.1016/j.ejso.2011.03.134

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  7 in total

1.  Ascites do not affect the rate of complete cytoreductive surgery and prognosis in patients with primary ovarian cancer with ascites treated with hyperthermic intraperitoneal chemotherapy.

Authors:  Mingchen Ba; Hui Long; Xiangliang Zhang; Zhaofei Yan; Shuai Wang; Yinbing Wu; Yuanfeng Gong; Shuzhong Cui
Journal:  Oncol Lett       Date:  2019-06-19       Impact factor: 2.967

2.  Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy.

Authors:  Daniel L Chan; David L Morris; Archana Rao; Terence C Chua
Journal:  Cancer Manag Res       Date:  2012-11-23       Impact factor: 3.989

3.  Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy to Treat Advanced/Recurrent Epithelial Ovarian Cancer: Results from a Retrospective Study on Prospectively Established Database.

Authors:  Jian-Hua Sun; Zhong-He Ji; Yang Yu; Hai-Tao Wu; Chao-Qun Huang; Qian Zhang; Xiao-Jun Yang; Yutaka Yonemura; Yan Li
Journal:  Transl Oncol       Date:  2016-04       Impact factor: 4.243

Review 4.  Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Overview of the Molecular and Cellular Mechanisms of Actions and Effects on Epithelial Ovarian Cancers.

Authors:  Pei-Qi Lim; I-Hung Han; Kok-Min Seow; Kuo-Hu Chen
Journal:  Int J Mol Sci       Date:  2022-09-03       Impact factor: 6.208

5.  Nasogastric- vs. percutaneous gastrostomy tube for prophylactic gastric decompression after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.

Authors:  Job P van Kooten; Nadine L de Boer; Marjolein Diepeveen; Cornelis Verhoef; Jacobus W A Burger; Alexandra R M Brandt-Kerkhof; Eva V E Madsen
Journal:  Pleura Peritoneum       Date:  2021-03-24

6.  Dense hyperthermic intraperitoneal chemotherapy with cisplatin in patients with stage III serous epithelial ovarian cancer: a retrospective study.

Authors:  Xiaoli He; Li Wei; Rui Li; Shuang Jing; Linlin Jia; Danwei Ji; Yali Li; Yue Wang; Yongxia Zhu
Journal:  BMC Cancer       Date:  2021-06-27       Impact factor: 4.430

Review 7.  Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.

Authors:  McKayla J Riggs; Prakash K Pandalai; Joseph Kim; Charles S Dietrich
Journal:  Diagnostics (Basel)       Date:  2020-01-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.